ranibizumab-eqrn
Drug Details
- Generic Name
- ranibizumab-eqrn
- Brand Names
- CIMERLI
- Application Number
- BLA761165
- Sponsor
- Coherus BioSciences Inc
- NDC Codes
- 4
- Dosage Forms
- INJECTION, SOLUTION
- Routes
- INTRAVITREAL
- Active Ingredients
- RANIBIZUMAB
Indications and Usage
1 INDICATIONS AND USAGE CIMERLI is indicated for the treatment of patients with: CIMERLI, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.2 ) Diabetic Macular Edema (DME) ( 1.3 ) Diabetic Retinopathy (DR) ( 1.4 ) Myopic Choroidal Neovascularization (mCNV) ( 1.5 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) 1.5 Myopic Choroidal Neovascularization (mCNV)